~28 spots leftby Sep 2026

Retinal Blood Flow Assessment for Glaucoma

Recruiting in Palo Alto (17 mi)
+3 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Recruiting
Sponsor: University of Maryland, Baltimore
Must not be taking: Glaucoma medications
Disqualifiers: Corneal abnormalities, Retinal disease, Secondary glaucoma, others
No Placebo Group
Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.

Will I have to stop taking my current medications?

If you have early glaucoma, you will need to stop taking your glaucoma medications for four weeks before participating in the study. If you cannot safely stop these medications, you may not be eligible to participate.

What data supports the effectiveness of the treatment Indocyanine Green Angiography and Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO) for glaucoma?

Research shows that Optical Coherence Tomography Angiography (OCT-A) is effective in analyzing retinal blood flow, which is important for understanding and monitoring glaucoma. Additionally, Adaptive Optics (AO) combined with OCT provides high-resolution images of the retina, helping to visualize microscopic structures and potentially detect early glaucomatous changes.12345

Is the retinal imaging technology used in the clinical trial safe for humans?

The imaging technologies mentioned, such as Optical Coherence Tomography (OCT) and Adaptive Optics (AO), are noninvasive and have been widely used in clinical settings for retinal imaging, suggesting they are generally safe for human use.12678

How does the treatment in the Retinal Blood Flow Assessment for Glaucoma trial differ from other treatments for glaucoma?

This treatment uses optical coherence tomography angiography (OCTA) to non-invasively measure and analyze retinal blood flow, which is unique compared to traditional glaucoma treatments that focus on reducing intraocular pressure through medication, laser, or surgery. OCTA provides detailed insights into blood flow and vessel density, potentially offering a more tailored approach to managing glaucoma progression.19101112

Research Team

Eligibility Criteria

This trial is for adults over 18 with early or pre-perimetric glaucoma, and a control group without glaucoma. Participants must not have had ocular surgery (except cataract surgery/laser trabeculoplasty), no diabetes/hypertension/vascular disorders, no retinal diseases affecting the nerve layer, non-smokers for at least 6 months, and able to be off glaucoma meds for four weeks.

Inclusion Criteria

Open angle in gonioscopy (grade 3 or 4 in Shaffer classification)
Individuals recruited will be in one of the 3 groups:
Best-corrected visual acuity 20/25 or better
See 6 more

Exclusion Criteria

I have been diagnosed with secondary glaucoma.
Inability to safely be off of glaucoma medications for 4 weeks
Any history of smoking in the past 6 months
See 7 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Initial assessment of retinal blood flow and autoregulation using EMAf and mAO techniques

1-2 weeks

Treatment

Participants receive isocapnic oxygen to evaluate retinal blood flow response

3 years

Follow-up

Participants are monitored for changes in retinal blood flow and autoregulation over time

4-8 weeks

Treatment Details

Interventions

  • Indocyanine Green Angiography (Diagnostic Test)
  • Isocapnic Oxygen (Gas)
  • Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO) (Diagnostic Test)
Trial OverviewThe study tests how well blood flow in the retina adjusts itself in people with early-stage open-angle glaucoma using Indocyanine Green Angiography, Isocapnic Oxygen inhalation, and advanced imaging techniques like OCT and AO to potentially identify new biomarkers.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Isocapnic OxygenExperimental Treatment3 Interventions
Investigators will evaluate retinal blood flow in response to oxygen supplementation.

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
University of Maryland, BaltimoreBaltimore, MD
University of Maryland Faculty Physicians, IncBaltimore, MD
Food and Drug Administration (FDA)Silver Spring, MD
University of Maryland Medical CenterBaltimore, MD
Loading ...

Who Is Running the Clinical Trial?

University of Maryland, Baltimore

Lead Sponsor

Trials
729
Patients Recruited
540,000+

Findings from Research

In a study involving 30 glaucoma patients and 21 healthy individuals, it was found that glaucoma patients have significantly reduced macular flow density in both the superficial and deep retinal plexus, indicating potential vascular changes associated with the disease.
The reduced flow density in glaucoma patients was independent of retinal thickness and nerve fiber layer measurements, suggesting that alterations in ocular blood flow may play a critical role in glaucoma development.
Optical coherence tomography angiography analysis of macular flow density in glaucoma.Kromer, R., Glusa, P., Framme, C., et al.[2019]
Adaptive optics-optical coherence tomography: optimizing visualization of microscopic retinal structures in three dimensions.Zawadzki, RJ., Choi, SS., Jones, SM., et al.[2022]
Optical Coherence Tomography Angiography in Neurodegenerative Diseases: A Review.Tsokolas, G., Tsaousis, KT., Diakonis, VF., et al.[2022]
High-resolution imaging of diabetic retinopathy lesions using an adaptive optics retinal camera.Cristescu, IE., Ochinciuc, R., Balta, F., et al.[2020]
Adaptive optics and the eye (super resolution OCT).Miller, DT., Kocaoglu, OP., Wang, Q., et al.[2022]
The study introduced ultrahigh-resolution adaptive optics-optical coherence tomography (UHR-AO-OCT) for detailed in vivo imaging of retinal structures, enhancing visualization of the macula and optic nerve head.
New visualization techniques were developed to improve data interpretation, including co-registering AO-OCT images with fundus photography and creating large field of view high-resolution volumes, which could aid in better understanding retinal conditions.
Cellular resolution volumetric in vivo retinal imaging with adaptive optics-optical coherence tomography.Zawadzki, RJ., Choi, SS., Fuller, AR., et al.[2021]
Adaptive-optics optical coherence tomography for high-resolution and high-speed 3D retinal in vivo imaging.Zawadzki, RJ., Jones, SM., Olivier, SS., et al.[2022]
Optical coherence tomography angiography (OCTA) is a noninvasive imaging technique that effectively visualizes retinal blood vessels and can detect changes in blood flow associated with glaucoma, showing reduced vessel density and loss of choriocapillaris in affected areas.
OCTA measurements correlate well with functional and structural changes in glaucoma, making it a valuable tool for diagnosing the disease, monitoring its progression, and assessing the risk of faster deterioration in patients.
Optical Coherence Tomography Angiography in Glaucoma.Rao, HL., Pradhan, ZS., Suh, MH., et al.[2022]
Measuring and interpreting ocular blood flow and metabolism in glaucoma.Harris, A., Kagemann, L., Ehrlich, R., et al.[2016]
In a study involving 58 patients with normal tension glaucoma and 44 healthy subjects, retinal blood flow (RBF) measurements using Doppler OCT were found to be significantly reduced in both damaged and normal hemispheres of glaucoma eyes, indicating potential for early detection.
The combination of retinal nerve fiber layer thickness (RNFLT) and RBF measurements improved diagnostic accuracy for glaucoma, achieving an area under the curve (AUC) of 0.987 in damaged hemispheres, suggesting that integrating these methods could enhance glaucoma diagnosis.
Glaucoma Diagnostic Performance of Retinal Blood Flow Measurement With Doppler Optical Coherence Tomography.Abe, T., Yoshioka, T., Song, Y., et al.[2022]
Repeatability and reproducibility of optic nerve head perfusion measurements using optical coherence tomography angiography.Chen, CL., Bojikian, KD., Xin, C., et al.[2022]
Optical coherence tomography angiography in glaucoma: analysis of the vessel density-visual field sensitivity relationship.Holló, G.[2020]

References

Optical coherence tomography angiography analysis of macular flow density in glaucoma. [2019]
Adaptive optics-optical coherence tomography: optimizing visualization of microscopic retinal structures in three dimensions. [2022]
Optical Coherence Tomography Angiography in Neurodegenerative Diseases: A Review. [2022]
High-resolution imaging of diabetic retinopathy lesions using an adaptive optics retinal camera. [2020]
Adaptive optics and the eye (super resolution OCT). [2022]
Cellular resolution volumetric in vivo retinal imaging with adaptive optics-optical coherence tomography. [2021]
Adaptive-optics optical coherence tomography for high-resolution and high-speed 3D retinal in vivo imaging. [2022]
Optical Coherence Tomography Angiography in Glaucoma. [2022]
Measuring and interpreting ocular blood flow and metabolism in glaucoma. [2016]
10.United Statespubmed.ncbi.nlm.nih.gov
Glaucoma Diagnostic Performance of Retinal Blood Flow Measurement With Doppler Optical Coherence Tomography. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Repeatability and reproducibility of optic nerve head perfusion measurements using optical coherence tomography angiography. [2022]
Optical coherence tomography angiography in glaucoma: analysis of the vessel density-visual field sensitivity relationship. [2020]